As Uganda expands access to lenacapavir, a twice-yearly injectable HIV prevention medicine, health experts have cautioned users to observe important precautions, particularly regarding other medicines they may be taking.
Lenacapavir, administered every six months, is emerging as a major addition to Uganda’s HIV prevention programme, with the Ministry of Health gradually increasing the number of health facilities offering the injection.
However, Dr Flavia Matovu Kiweewa, Director of Research at the MU-JHU Research Collaboration and Uganda’s National Principal Investigator for the Gilead-sponsored PURPOSE 1 study, says people should not treat lenacapavir as an ordinary injection that can be obtained and used without medical assessment.